REG - Adv Medical Solutns. - Timing of AGM and Change of Dividend Record Date

Advanced Medical SolutionsAnnouncement

14/05/2025 15:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250514:nRSN6987Ia&default-theme=true

RNS Number : 6987I  Advanced Medical Solutions Grp PLC  14 May 2025

     14 May 2025

            Advanced Medical Solutions Group plc

("AMS", the "Company" or the "Group")

 

            Timing of AGM
            and
            Change of Record Date for Final Dividend
 

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the
world-leading specialist in tissue-healing technologies, announces that, as a
consequence of unforeseen changes within the audit team at Deloitte LLP, and
the associated delay in expected signing date of the Annual Report and
Accounts, the Company now expects its Annual General Meeting ("AGM") to be
held on 30 June 2025. Subsequently, following the announcement of our FY24
Unaudited Preliminary Results (issued at 07:00 on 19 March 2025 under RNS
2726B), we are changing the record date for our proposed final dividend of
1.83p per share to 20 June 2025.

 

As a result of this change, and subject to approval by shareholders at the
forthcoming AGM, the proposed final dividend will be paid on 17 July 2025 to
shareholders on the register at the close of business on 20 June 2025.

 

 

- End -

 

For further information, please visit www.admedsol.com
(http://www.admedsol.com) or contact:

 

 Advanced Medical Solutions Group plc     Tel: +44 (0) 1606 545508
 Chris Meredith, Chief Executive Officer

 Eddie Johnson, Chief Financial Officer

 Michael King, Investor Relations

 ICR Healthcare                           Tel: +44 (0) 20 3709 5700
 Mary-Jane Elliott / Lucy Featherstone    AMS@icrhealthcare.com

 Investec Bank PLC (NOMAD & Broker)       Tel: +44 (0) 20 7597 5970
 Gary Clarence / David Anderson

 

About Advanced Medical Solutions Group plc - see www.admedsol.com
(http://www.admedsol.com)

AMS is a world-leading independent developer and manufacturer of innovative
tissue-healing technology, focused on quality outcomes for patients and value
for payers. AMS has a wide range of surgical products including tissue
adhesives, sutures, haemostats, internal fixation devices and internal
sealants, which it markets under its brands LiquiBand®, RESORBA®,
LiquiBandFix8®, LIQUIFIX™, Peters Surgical, Ifabond, Vitalitec and
Seal-G®. AMS also supplies wound care dressings such as silver alginates,
alginates and foams through its ActivHeal® brand as well as under white
label. Since 2019, the Group has made seven acquisitions: Sealantis, an
Israeli developer of innovative internal sealants, Biomatlante, a French
developer and manufacturer of surgical biomaterials, Raleigh, a leading UK
coater and converter of woundcare and bio-diagnostics materials, AFS Medical,
an Austrian specialist surgical business, Connexicon, an Irish tissue
adhesives specialist, Syntacoll, a German specialist in collagen-based
absorbable surgical implants and Peters Surgical, a global provider of
specialty surgical sutures, mechanical haemostasis and internal cyanoacrylate
devices.

 

AMS's products, manufactured in the UK, Germany, France, the Netherlands,
Thailand, India, the Czech Republic and Israel, are sold globally via a
network of multinational or regional partners and distributors, as well as via
AMS's own direct sales forces in the UK, Germany, Austria, France, Poland,
Benelux, India, the Czech Republic and Russia. The Group has R&D
innovation hubs in the UK, Ireland, Germany, France and Israel. Established in
1991, the Group has more than 1,600 employees. For more information, please
see www.admedsol.com (http://www.admedsol.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDEADSLFSXSEFA